244 related articles for article (PubMed ID: 28560458)
61.
Ye S; Hu X; Ni C; Jin W; Xu Y; Chang L; Zhou H; Jiang J; Yang L
Mol Cancer Ther; 2020 Mar; 19(3):956-965. PubMed ID: 31924740
[TBL] [Abstract][Full Text] [Related]
62. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.
Rodríguez J; Zarate R; Bandres E; Boni V; Hernández A; Sola JJ; Honorato B; Bitarte N; García-Foncillas J
Eur J Cancer; 2012 Aug; 48(12):1774-80. PubMed ID: 22305465
[TBL] [Abstract][Full Text] [Related]
63. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
Bronte G; Silvestris N; Castiglia M; Galvano A; Passiglia F; Sortino G; Cicero G; Rolfo C; Peeters M; Bazan V; Fanale D; Giordano A; Russo A
Oncotarget; 2015 Sep; 6(28):24780-96. PubMed ID: 26318427
[TBL] [Abstract][Full Text] [Related]
64. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
65. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
66. EphA2 promotes cell adhesion and spreading of monocyte and monocyte/macrophage cell lines on integrin ligand-coated surfaces.
Saeki N; Nishino S; Shimizu T; Ogawa K
Cell Adh Migr; 2015; 9(6):469-82. PubMed ID: 26565750
[TBL] [Abstract][Full Text] [Related]
67. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
68. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer.
Lee PC; Chen ST; Kuo TC; Lin TC; Lin MC; Huang J; Hung JS; Hsu CL; Juan HF; Lee PH; Huang MC
Oncogene; 2020 Mar; 39(13):2724-2740. PubMed ID: 32005975
[TBL] [Abstract][Full Text] [Related]
69. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
[TBL] [Abstract][Full Text] [Related]
70. Mutation-specific effects of NRAS oncogenes in colorectal cancer cells.
Kuhn N; Klinger B; Uhlitz F; Sieber A; Rivera M; Klotz-Noack K; Fichtner I; Hoffmann J; Blüthgen N; Falk C; Sers C; Schäfer R
Adv Biol Regul; 2021 Jan; 79():100778. PubMed ID: 33431353
[TBL] [Abstract][Full Text] [Related]
71. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F
Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856
[No Abstract] [Full Text] [Related]
72. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
73. ADAM12-cleaved ephrin-A1 contributes to lung metastasis.
Ieguchi K; Tomita T; Omori T; Komatsu A; Deguchi A; Masuda J; Duffy SL; Coulthard MG; Boyd A; Maru Y
Oncogene; 2014 Apr; 33(17):2179-90. PubMed ID: 23686306
[TBL] [Abstract][Full Text] [Related]
74. Age-associated defects in EphA2 signaling impair the migration of human cardiac progenitor cells.
Goichberg P; Kannappan R; Cimini M; Bai Y; Sanada F; Sorrentino A; Signore S; Kajstura J; Rota M; Anversa P; Leri A
Circulation; 2013 Nov; 128(20):2211-23. PubMed ID: 24141256
[TBL] [Abstract][Full Text] [Related]
75. Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer.
Lee HY; Mohammed KA; Kaye F; Sharma P; Moudgil BM; Clapp WL; Nasreen N
Int J Nanomedicine; 2013; 8():4481-94. PubMed ID: 24293999
[TBL] [Abstract][Full Text] [Related]
76. Effect of ephrin-A1/EphA2 on invasion of trophoblastic cells.
Yang Y; Min J
J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):824-827. PubMed ID: 22173506
[TBL] [Abstract][Full Text] [Related]
77. Theoretical Model of EphA2-Ephrin A1 Inhibition.
Jedwabny W; Lodola A; Dyguda-Kazimierowicz E
Molecules; 2018 Jul; 23(7):. PubMed ID: 29997324
[TBL] [Abstract][Full Text] [Related]
78. Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.
Toma MI; Erdmann K; Diezel M; Meinhardt M; Zastrow S; Fuessel S; Wirth MP; Baretton GB
PLoS One; 2014; 9(7):e102262. PubMed ID: 25025847
[TBL] [Abstract][Full Text] [Related]
79. Eph/ephrin signalling serves a bidirectional role in lipopolysaccharide‑induced intestinal injury.
Xiong Y; Li KX; Wei H; Jiao L; Yu SY; Zeng L
Mol Med Rep; 2018 Aug; 18(2):2171-2181. PubMed ID: 29901151
[TBL] [Abstract][Full Text] [Related]
80. Ephs and ephrins in cancer: ephrin-A1 signalling.
Beauchamp A; Debinski W
Semin Cell Dev Biol; 2012 Feb; 23(1):109-15. PubMed ID: 22040911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
